A Phase 1, Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Nebulized Ensifentrine in Healthy Chinese Subjects
Latest Information Update: 26 Apr 2023
At a glance
- Drugs Ensifentrine (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- 20 Apr 2023 Status changed from recruiting to completed.
- 29 Mar 2023 Status changed from not yet recruiting to recruiting.
- 09 Mar 2023 According to a Nuance Pharma media release, first healthy subject has been dosed in this trial.